

Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the β_1 -thyroid hormone receptor

H.C. van Beeren*, O. Bakker, W.M. Wiersinga

Department of Endocrinology, Academic Medical Centre F5-171, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Received 2 August 2000; accepted 16 August 2000

Edited by Jacques Hanoune

Abstract Ligand binding to the thyroid hormone nuclear receptor β_1 (TR β_1) is inhibited by desethylamiodarone (DEA), the major metabolite of the widely used anti-arrhythmic drug amiodarone. Gene expression of thyroid hormone (triiodothyronine, T₃)-regulated genes can therefore be affected by amiodarone due to less ligand binding to the receptor. Previous studies have indicated the possibility of still other explanations for the inhibitory effects of amiodarone on T₃-dependent gene expression, probably via interference with receptor/co-activator and co-repressor complex. The binding site of DEA is postulated to be on the outside surface of the receptor protein overlapping the regions where co-activator and co-repressor bind. Here we show the effect of a drug metabolite on the interaction of TR β_1 with the co-activator GRIP-1 (glucocorticoid receptor interacting protein-1). The T₃-dependent binding of GRIP-1 to the TR β_1 is disrupted by DEA. A DEA dose experiment showed that the drug metabolite acts like an antagonist under 'normal' conditions (at 10^{-7} M T₃ and $5 \times 10^{-6} \rightarrow 10^{-3}$ M DEA), but as an agonist under extreme conditions (at 0 and 10^{-9} M T₃ and $> 10^{-4}$ M DEA). To our knowledge, these results show for the first time that a metabolite of a drug which was not devised for this purpose can interfere with nuclear receptor/co-activator interaction. © 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.

Key words: Desethylamiodarone;
Co-activator glucocorticoid receptor interacting protein-1;
Thyroid hormone receptor

1. Introduction

Hormones can influence transcription via binding to their specific nuclear receptors. Occupancy of binding sites with ligand results in conformational changes of the receptor protein, allowing dissociation of co-repressors and association of the hormone–receptor complex with nuclear co-activators. This sequence of events ultimately leads to modulation of the transcription rate of the hormone-responsive genes [1]. The role of nuclear co-repressors and co-activators in transcriptional regulation has only recently become apparent. Their biological relevance is highlighted by the finding that particular mutations in the human thyroid hormone receptor β_1 (hTR β_1) disturb the interaction between co-activator and co-repressor interactions and thyroid hormone receptor (TR), resulting in thyroid hormone resistance [2]. Desethylamiodarone (DEA), the major metabolite of the powerful anti-arrhythmic and anti-anginal drug amiodarone, is a non-compet-

itive inhibitor of the binding of triiodothyronine (T₃) to the thyroid hormone receptor β_1 (TR β_1) protein [3], its binding site is postulated to be on the outside surface of the receptor protein overlapping the regions where co-activator and co-repressor bind [4]. Here we report that DEA can also affect the binding of co-activator glucocorticoid receptor interacting protein-1 (GRIP-1) to the ligand–receptor complex.

Amiodarone is widely used in the treatment of a variety of cardiac diseases. It is a peculiar drug in view of its extensive tissue accumulation (notably in the liver, lung and adipose tissue) and very long elimination half-life. Characteristic structural features are its resemblance to thyroxine and its high iodine content. The release of pharmacological quantities of iodine during biotransformation of the drug results in iodine-induced thyrotoxicosis and hypothyroidism in a minority (about 16%) of patients. In contrast, in almost every patient treated with amiodarone, hypothyroid-like effects are observed in the expression of various T₃-responsive genes. Examples are the decrease in β -adrenoreceptor density and Na,K-ATPase activity in the heart, and the decrease of low density lipid (LDL) receptor density in the liver as evident from studies in humans and in experimental animals [5–8]. These hypothyroid-like effects can be reversed by the administration of T₃, and are explained from a decreased transcription of involved genes [9]. For example, the increase in serum LDL cholesterol observed in amiodarone-treated patients [10] is caused by a decreased expression of the hepatic LDL receptor protein, which is due to a decreased transcription of the gene encoding the LDL receptor. The decrease in transcription might well be caused by a lower T₃ receptor occupancy as amiodarone substantially decreases the generation of T₃ out of T₄ in the liver by inhibition of type I deiodinase [11]. Furthermore, DEA has been shown to be a competitive inhibitor of the binding of T₃ to thyroid hormone receptor α_1 (TR α_1) [12] and a non-competitive inhibitor with respect to TR β_1 [3]. Further insight into this antagonistic effect of DEA on T₃ receptor binding was obtained by evaluating the changes in the molecular constitution of either the drug or the receptor. We have previously reported the results of competition studies with amiodarone analogues: the bulky iodine atoms, the hydrophobicity, the electric charge and the overall size of the analogues markedly influenced the nature and potency of their inhibition on T₃ receptor binding [13]. These studies, however, did not provide further information on the localization of the DEA binding site on the receptor. Therefore we studied the effect of naturally occurring and artificial mutations in TR β_1 which were known to decrease T₃ affinity. The results of these studies demonstrated that amino acids E457 and R429 are at or near the DEA binding site on the receptor [4]. Since these residues may be involved in co-acti-

*Corresponding author. Fax: (31)-20-691 7682.
E-mail: h.c.vanbeeren@amc.uva.nl

vator (E457) [14] or co-repressor (R429) [15,16] interaction, this finding led us to hypothesize a possible disruption of the TR β_1 -co-activator interaction by DEA. The aim of the present study was to verify this hypothesis by studying the influence of DEA on the T $_3$ -dependent binding of co-activator GRIP-1 to hTR β_1 .

2. Materials and methods

2.1. Chemicals

T $_3$ was obtained from Henning (Berlin, Germany). DEA from Sanofi Recherche (Montpellier, France) was used as a 10⁻² M stock solution in ethanol.

2.2. Protein expression

Co-activator GRIP-1 was expressed as a glutathione-S-transferase (GST)-GRIP-1-nuclear receptor interacting domain (NID) fusion protein containing the NID of the co-activator GRIP-1 attached to GST. This fusion protein was expressed in *Escherichia coli* as described previously [17].

TR β_1 (amino acids 153–461) was cloned with a hemagglutinin epitope-tag (HA-TR β_1) at the N-terminus which did not interfere with the hormone binding domain at the C-terminus. The HA-TR β_1 was expressed in *E. coli* and isolated as described before [17,18].

2.3. Pull-down assay

To study the receptor co-activator interaction in the presence of DEA, we used a recently developed non-radioactive 'pull-down' assay [18]. In short, GST-GRIP-1-NID bound to glutathione-Sepharose beads was resuspended in binding buffer (20 mM HEPES, pH 7.9, 80 mM KCl, 10 mM MgCl₂, 10% glycerol, 1 mM dithiothreitol (DTT), 0.1% NP-40, 0.1% Triton X-100; Complete (EDTA free) protease inhibitor (Roche)). HA-TR β_1 -containing lysate (8 μ l) was diluted to 20 μ l with binding buffer containing 20 μ l/ml bovine serum albumin and preincubated with or without T $_3$ and in the absence or presence of DEA for 30 min at 4°C. Thereafter GST-GRIP-1-NID beads were added and the incubation continued for 90 min at 4°C whilst shaking. The samples were washed, dried and resuspended in protein loading buffer containing 5 mM DTT. They were run on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis gel blotted onto PVDF membrane (Roche) using a transfer buffer without SDS and lowered methanol (15%).

For detection of the HA-tag, the blot was incubated with a high affinity monoclonal anti-HA antibody conjugated with peroxidase (POD) (anti-HA 3F10-POD). Using Lumi-Light^{plus} substrate (Roche), the chemiluminescent signal was detected and quantified using a Lumi Imager (Roche). Average exposure time was 2 min.

To investigate whether DEA had an effect on this protein-protein interaction two sets of experiments were performed. First the dose effect of T $_3$ was studied in the absence and presence of a constant amount of DEA. TR β_1 was preincubated with thyroid hormone (T $_3$) over a concentration range of 3 \times 10⁻¹⁰ up to 10⁻⁷ M T $_3$ in the absence and presence of 10⁻⁵ M DEA. In the second set of experiments, the dose-dependent effect of DEA was studied. TR β_1 was preincubated with DEA over a concentration range of 10⁻⁶ up to 10⁻³ M DEA in the absence of T $_3$ and in the presence of 10⁻⁹ M and 10⁻⁷ M T $_3$.

3. Results

The results of the T $_3$ dose effect experiments indicate a T $_3$ dose dependency of the binding of GRIP-1 to the TR β_1 , which was observed previously [19]. The binding of GRIP-1 to the TR β_1 increased at higher T $_3$ and was lower in the presence of 10⁻⁵ M DEA at all T $_3$ concentrations tested (Fig. 1a) ($P < 0.0001$; ANOVA, two way with replication; $n = 3$). Individual points of the binding curves differ significantly at 3 \times 10⁻⁸ M ($P < 0.01$; $n = 5$) and at 10⁻⁷ M ($P < 0.05$; $n = 4$) (Fig. 1b). The HA-TR β_1 protein binds T $_3$ with wild type affinity (K_D 0.3 \times 10⁻⁹ M).




Fig. 1. a: Western blots of HA-TR β_1 , depicting the dose-dependent effect of T $_3$ on the binding of TR β_1 to GRIP-1 in the absence and presence of 10⁻⁵ M DEA. Lane 1: 10% of HA-TR β_1 input. Lanes 2–8: binding in the presence of 0; 3 \times 10⁻¹⁰; 6 \times 10⁻¹⁰; 10⁻⁹; 3 \times 10⁻⁹; 3 \times 10⁻⁸; 10⁻⁷ M T $_3$, respectively, in the absence of DEA. Lanes 9–15: binding in the presence of 0; 3 \times 10⁻¹⁰; 6 \times 10⁻¹⁰; 10⁻⁹; 3 \times 10⁻⁹; 3 \times 10⁻⁸; 10⁻⁷ M T $_3$, respectively, in the presence of 10⁻⁵ M DEA. HA-TR β_1 was detected by anti-HA-POD and chemiluminescent substrate. b: Dose-response effect of T $_3$ on the binding of TR β_1 to GRIP-1 in the absence (●) and presence (▲) of 10⁻⁵ M DEA. Quantification and plot of the light units from Western blot (a), measured by the Lumi Imager. The relative binding is the ratio of the observed binding of TR β_1 to GRIP-1 to the (maximal) binding at 10⁻⁷ M T $_3$ in the absence of DEA.

A DEA dose-dependent effect of the binding of GRIP-1 to the TR β_1 was also observed. In the absence of T $_3$, the binding of GRIP-1 to TR β_1 remains very low at DEA concentrations up to 10⁻⁵ M (Fig. 2a); however, a 10-fold increase is observed in the presence of 10⁻³ M DEA. It appears therefore that DEA acts as an agonist with respect to the unoccupied TR β_1 . In the presence of 10⁻⁹ M T $_3$, the DEA-induced increase in binding is less pronounced and significantly different from that obtained in the absence of T $_3$ ($P < 0.001$; ANOVA, two-factor with replication; $n = 4$) (Fig. 2b). Interestingly, at 10⁻⁷ M T $_3$, a reversal of the dose-response pattern is seen and the binding curve differs significantly from the other two ($P < 0.001$; ANOVA, two-factor with replication; $n = 4$). At a T $_3$ concentration of 10⁻⁷ M, the highest binding of GRIP-1 to TR β_1 is observed in the absence of DEA, and the binding decreases in the presence of DEA in a dose-dependent manner (Fig. 2a,b).

4. Discussion

From the above results, we conclude that DEA can act as a




Fig. 2. a: Western blots of HA-TR β_1 , depicting the dose-dependent effect of DEA on the binding of TR β_1 to GRIP-1 in the presence of 0, 10⁻⁹ or 10⁻⁷ M T₃. Lanes 1–6: binding in the absence of T₃ and in the presence of 0; 10⁻⁶; 5 × 10⁻⁶; 10⁻⁵; 10⁻⁴; 10⁻³ M DEA, respectively. Lanes 7–13: binding in the presence of 10⁻⁹ M T₃ and in the presence of 0; 10⁻⁶; 5 × 10⁻⁶; 10⁻⁵; 5 × 10⁻⁵; 10⁻⁴; 10⁻³ M DEA, respectively. Lanes 14–20: binding in the presence of 10⁻⁷ M T₃ and in the presence of 0; 10⁻⁶; 5 × 10⁻⁶; 10⁻⁵; 5 × 10⁻⁵; 10⁻⁴; 10⁻³ M DEA, respectively. Lane 21: 10% of HA-TR β_1 input. b: Dose-response effect of DEA on the binding of TR β_1 to GRIP-1 in the absence of T₃ (▲) and in the presence of 10⁻⁹ M T₃ (□) and 10⁻⁷ M T₃ (●). Quantification and plot of the light units from Western blot (a), measured by Lumi Imager. The light units are expressed as BLUs (Boehringer Light Units). The crossing of the lines at high and low T₃ concentration is indicative for partial antagonism.

partial antagonist: the actual mode of action depends on the ambient T₃ concentration. This phenomenon can be explained from the non-competitive nature of the inhibition of T₃ binding to TR β_1 by DEA. This non-competitiveness allows the formation of both the complexes DEA/TR β_1 and DEA/T₃/TR β_1 , since the binding sites of T₃ and DEA are not the same. Only in the case of DEA/T₃/TR β_1 will there be antagonism, i.e. there must be some T₃ present for DEA to act as an antagonist.

In order to relate these *in vitro* findings to the *in vivo* situation, T₃ and DEA concentrations in our experiments must be compared with tissue levels *in vivo*. In human serum, T₃ values are in the order of 10⁻⁹ M and DEA levels in the order of 2 × 10⁻⁶ M [20] in patients on long-term amiodarone treatment. Rat liver T₃ and DEA levels are reported to be about 10⁻⁸ mol/kg [11] and 1.2 × 10⁻⁵ mol/kg [21], respectively. In human liver, DEA concentration can reach 4 × 10⁻³ mol/kg [22]. A thousand times higher DEA concentration in liver and other tissues compared to T₃ is therefore possible. The actual intracellular T₃ and DEA levels are not known, but taking into account the above mentioned serum and tissue concentrations, our *in vitro* model may well represent the *in vivo* situation in the human cell. DEA is a very lipophilic drug and accumulates substantially in tissues during

amiodarone treatment. The drug also inhibits T₄ 5'-deiodination into T₃ resulting in a substantial decrease of intracellular T₃ levels and lower TR occupancy [11]. At a 'normal' receptor occupancy of about 50%, the effect of DEA will be limited. However, at higher DEA concentrations and especially in the case of a decreased T₃ occupancy of the binding sites, DEA will act as an antagonist, resulting in lower co-activator binding.

Simplified, T₃-dependent gene regulation can be seen as an on/off switch (with or without ligand), whereas in the fine tuning of this process many other proteins are involved. This complex regulation system thus forms a balance between hormone, receptor, co-activators, co-repressors and other proteins involved in the transcription machinery. DEA interferes in this balance in three ways. First, by inhibiting deiodination of T₄ to T₃ in the liver [11]. Second, by a non-competitive inhibition of the binding of T₃ to the TR β_1 [3]. And third, by disrupting the binding of co-activator GRIP-1 to the TR β_1 (this study).

Overall we postulate that not amiodarone itself, but its stable major metabolite DEA interferes with T₃-dependent gene expression [23] by interfering with the binding of T₃ to the thyroid hormone receptor and disrupting the co-activator/TR binding. This mechanism of action would explain the T₃

antagonistic effects of DEA observed in patients on long-term amiodarone treatment.

Acknowledgements: The authors would like to thank Beatrice Darimont and Keith Yamamoto for providing the GST-GRIP-1-NID clone and for their helpful discussions and Paul Webb for his initial help in developing the non-radioactive pull-down protocol.

References

- [1] Shibata, H., Spencer, T.E., Oñate, S.A., Jenster, G., Tsai, S.Y., Tsai, M.J. and O'Malley, B.W. (1997) *Recent Prog. Horm. Res.* 52, 141–165.
- [2] Tagami, T., Gu, W.X., Peairs, P.T., West, B.L. and Jameson, J.L. (1998) *Mol. Endocrinol.* 12, 1888–1902.
- [3] Bakker, O., van Beeren, H.C. and Wiersinga, W.M. (1994) *Endocrinology* 134, 1665–1670.
- [4] Van Beeren, H.C., Bakker, O., Chatterjee, V.K.K. and Wiersinga, W.M. (1999) *FEBS Lett.* 450, 35–38.
- [5] Adli, H., Bazin, R. and Perret, G.Y. (1999) *Br. J. Pharmacol.* 126, 1455–1461.
- [6] Azuma, K., Magyar, C.E., Wang, J.K. and Mc Donough, A.A. (1995) *Am. J. Physiol.* 269, 675–682.
- [7] Hensley, C.B., Bersohn, M.M., Sarma, J.S., Singh, B.N. and Mc Donough, A.A. (1994) *J. Mol. Cell. Cardiol.* 26, 417–424.
- [8] Hudig, F., Bakker, O. and Wiersinga, W.M. (1994) *FEBS Lett.* 341, 86–90.
- [9] Hudig, F., Bakker, O. and Wiersinga, W.M. (1997) *J. Endocrinol.* 152, 413–421.
- [10] Wiersinga, W.M., Trip, M.D., van Beeren, H.C., Plomp, T.A. and Oosting, H. (1991) *Ann. Int. Med.* 114, 128–132.
- [11] Schröder-van der Elst, J.P. and van der Heide, D. (1990) *Endocrinology* 127, 1656–1664.
- [12] Van Beeren, H.C., Bakker, O. and Wiersinga, W.M. (1995) *Mol. Cell Endocrinol.* 112, 15–19.
- [13] Van Beeren, H.C., Bakker, O. and Wiersinga, W.M. (1996) *Endocrinology* 137, 2807–2814.
- [14] Collingwood, T.N., Rajanayagam, O., Adams, M., Wagner, R., Cavailles, V., Kalkhoven, E., Matthews, C., Nystrom, E., Stenlof, K., Lindstedt, G., Tisell, L., Fletterick, R.J., Parker, M.G. and Chatterjee, V.K.K. (1997) *Proc. Natl. Acad. Sci. USA* 94, 248–253.
- [15] Flynn, T.R., Hollenberg, A.N., Cohen, O., Menke, J.B., Usala, S.J., Tollin, S., Hegarty, M.K. and Wondisford, F.E. (1994) *J. Biol. Chem.* 269, 32713–32716.
- [16] Hayashi, Y., Weiss, R.E., Sarne, D.H., Yen, P.M., Sunthornthepvarakul, T., Marcocci, C., Chin, W.W. and Refetoff, S. (1995) *J. Clin. Endocrinol. Metab.* 80, 3246–3256.
- [17] Darimont, B.D., Wagner, R.L., Apriletti, J.W., Stallcup, M.R., Kushner, P.J., Baxter, J.D., Fletterick, R.J. and Yamamoto, K.R. (1998) *Genes Dev.* 12, 3343–3356.
- [18] Bakker, O., van Beeren, H.C. and Wiersinga, W.M. (1999) *Anal. Biochem.* 276, 105–106.
- [19] Clifton Bligh, R.J., de Zegher, F., Wagner, R.L., Collingwood, T.N., Francois, I., Van Helvoirt, M., Fletterick, R.J. and Chatterjee, V.K.K. (1998) *Mol. Endocrinol.* 12, 609–621.
- [20] Plomp, T.A., Hauer, R.N.W. and Robles de Medina, E.O. (1990) *In Vivo* 4, 97–100.
- [21] Plomp, T.A., Wiersinga, W.M. and Maes, R.A.A. (1985) *Arzneim.forsch. Drug Res.* 35, 122–129.
- [22] Holt, D.W., Tucker, T.G., Jackson, P.R. and Storey, G.C.A. (1983) *Am. Heart J.* 106, 843–847.
- [23] Drvota, V., Blange, I., Haggblad, J. and Sylven, C. (1998) *J. Cardiovasc. Pharmacol.* 32, 654–661.